Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "RAS"

1578 News Found

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Drug Approval | April 28, 2025

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein


FUJIFILM India to sell Spectra Logic’s tape storage products, software in India
News | April 25, 2025

FUJIFILM India to sell Spectra Logic’s tape storage products, software in India

Distribution agreement enables FUJIFILM India to offer Spectra Logic advanced tape libraries and software solutions to enterprise customers and channel partners


Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion
News | April 24, 2025

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience


WHO prequalifies Syngenta’s innovative insecticide Sovrenta
News | April 23, 2025

WHO prequalifies Syngenta’s innovative insecticide Sovrenta

A new weapon in the global fight against malaria


Gujarat CM Bhupendra Patel inaugurates 217-bed cancer hospital in Ahmedabad
Healthcare | April 22, 2025

Gujarat CM Bhupendra Patel inaugurates 217-bed cancer hospital in Ahmedabad

The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat


AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer
News | April 22, 2025

AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care


Injection filter needle market to reach $1.73 billion in 2025
Opinion | April 17, 2025

Injection filter needle market to reach $1.73 billion in 2025

Rising demands and advancements in eye care drive growth


Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
News | April 14, 2025

Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities